Skip to content

Study · Randomized controlled trial · n = 3,791 · 2025

6 results

Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.

Peters AL, Buzzetti R, Lee CJ, Pavo I, Liu M, Karanikas CA, Paik JS

The Journal of clinical endocrinology and metabolism1 Mar 2025Cited by 6 (Europe PMC)

PMID38824910 (opens in a new tab)PMCIDPMC11913103 (opens in a new tab)DOI10.1210/clinem/dgae372 (opens in a new tab)PepBankPUB-38824910
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In GADA-negative adults with type 2 diabetes, tirzepatide reduced HbA1c by 2.32% from baseline at week 40/42.

    In plain wordsIn adults with type 2 diabetes and no GADA antibodies, tirzepatide lowered HbA1c by 2.32% at about 40 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change in GADA-negative participants
    Study

    n = 3,671

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 42 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.32%
    GADA-negative

    Source sentences

    Summary
    At week 40/42, both groups achieved robust reductions in HbA1c (-2.11% vs -2.32%) and BW (-9.2 kg vs -9.6 kg) (P < .001, both groups).
    2 context sentences
    Summary · context
    Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals.
    Summary · context
    Intervention included tirzepatide (5, 10, 15 mg).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In GADA-positive adults with a clinical type 2 diabetes diagnosis, tirzepatide reduced HbA1c by 2.11% from baseline at week 40/42.

    In plain wordsIn adults with a type 2 diabetes diagnosis and GADA antibodies, tirzepatide lowered HbA1c by 2.11% at about 40 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change in GADA-positive participants
    Study

    n = 120

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 42 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.11%
    GADA-positive

    Source sentences

    Summary
    At week 40/42, both groups achieved robust reductions in HbA1c (-2.11% vs -2.32%) and BW (-9.2 kg vs -9.6 kg) (P < .001, both groups).
    2 context sentences
    Summary · context
    Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals.
    Summary · context
    Intervention included tirzepatide (5, 10, 15 mg).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with a clinical type 2 diabetes diagnosis on tirzepatide, HbA1c reductions were greater in GADA-negative than in GADA-positive participants (estimated difference 0.21%).

    In plain wordsIn adults with type 2 diabetes on tirzepatide, HbA1c fell a little more in people without GADA antibodies than in people with them.

    Peptide
    Tirzepatide
    Outcome
    Not applicableHbA1c reduction, GADA-negative versus GADA-positive
    Study

    n = 3,791

    Comparator
    GADA-negative participants
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 42 weeksAs given in this study (human).

    Measurements

    Estimated difference in HbA1c reduction
    0.21%
    GADA-negative vs GADA-positive

    Source sentences

    Summary
    HbA1c reductions were greater in GADA-negative participants (estimated difference [95% CI]: 0.21% [0.03, 0.39]; P = .024)
    2 context sentences
    Summary · context
    Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals.
    Summary · context
    Intervention included tirzepatide (5, 10, 15 mg).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with a clinical type 2 diabetes diagnosis on tirzepatide, body weight reductions did not differ between GADA-positive and GADA-negative participants (0.38 kg).

    In plain wordsIn adults with type 2 diabetes on tirzepatide, weight loss was not clearly different between people with and without GADA antibodies.

    Peptide
    Tirzepatide
    Outcome
    No significant changeBody weight reduction, GADA-positive versus GADA-negative
    Study

    n = 3,791

    Comparator
    GADA-negative participants
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 42 weeksAs given in this study (human).

    Measurements

    Estimated difference in body weight reduction
    0.38 kg
    GADA-positive vs GADA-negative

    Source sentences

    Summary
    BW reductions did not differ between groups (0.38 kg [-0.99, 1.75]; P = .588).
    2 context sentences
    Summary · context
    Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals.
    Summary · context
    Intervention included tirzepatide (5, 10, 15 mg).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In GADA-negative adults with type 2 diabetes, tirzepatide reduced body weight by 9.6 kg from baseline at week 40/42.

    In plain wordsIn adults with type 2 diabetes and no GADA antibodies, tirzepatide lowered body weight by 9.6 kg at about 40 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change in GADA-negative participants
    Study

    n = 3,671

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 42 weeksAs given in this study (human).

    Measurements

    Body weight change
    −9.6 kg
    GADA-negative

    Source sentences

    Summary
    At week 40/42, both groups achieved robust reductions in HbA1c (-2.11% vs -2.32%) and BW (-9.2 kg vs -9.6 kg) (P < .001, both groups).
    2 context sentences
    Summary · context
    Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals.
    Summary · context
    Intervention included tirzepatide (5, 10, 15 mg).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In GADA-positive adults with a clinical type 2 diabetes diagnosis, tirzepatide reduced body weight by 9.2 kg from baseline at week 40/42.

    In plain wordsIn adults with a type 2 diabetes diagnosis and GADA antibodies, tirzepatide lowered body weight by 9.2 kg at about 40 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change in GADA-positive participants
    Study

    n = 120

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 42 weeksAs given in this study (human).

    Measurements

    Body weight change
    −9.2 kg
    GADA-positive

    Source sentences

    Summary
    At week 40/42, both groups achieved robust reductions in HbA1c (-2.11% vs -2.32%) and BW (-9.2 kg vs -9.6 kg) (P < .001, both groups).
    2 context sentences
    Summary · context
    Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals.
    Summary · context
    Intervention included tirzepatide (5, 10, 15 mg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.